A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Number of Participants with Adverse Events

Time frame · Up to 36 months

An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Number of Participants with Serious Adverse Events

Time frame · Up to 36 months

A serious AE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability /incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.

Changes from Baseline in Prescription Volume of Parenteral Nutrition Intravenous (PN/IV) Support

Time frame · Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation

Changes from baseline in prescription volume of PN/IV support prescribed by investigators to 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation will be reported.

Percent Change from Baseline in Prescription Volume of PN/IV Support

Time frame · Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation

Percent change from baseline in prescription volume of PN/IV support to multiple timepoints (6, 12, 18, 24, 30, and 36 months) after teduglutide treatment initiation will be reported. Percent change from baseline will be calculated as following; \[prescription volume at each timepoint - prescription volume at baseline\] / prescription volume at baseline \* 100 (percent).

Changes from Baseline in Dose of PN/IV Support

Time frame · Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation

Changes from baseline in actual dose of PN/IV support to 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation will be reported.

Percent Change from Baseline of Dose in PN/IV Support

Time frame · Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation

Percent change from baseline in actual dose of PN/IV support to multiple timepoints (6, 12, 18, 24, 30, and 36 months) after teduglutide treatment initiation will be reported. Percent change from baseline will be calculated as following; \[actual dose at each timepoint - actual dose at baseline\] / actual dose at baseline \* 100 (percent).

Percentage of Participants who Completely Wean off PN/IV Support

Time frame · Baseline, 6, 12, 18, 24, 30, and 36 months after teduglutide treatment initiation

Number of participants who completely wean off PN/IV support will be assessed.

Crohn's Disease Activity Index (CDAI)

Time frame · 36 months after teduglutide treatment initiation

CDAI score is calculated from the following 8 items: (a) Number of liquid or very soft stools; (b) Abdominal pain; (c) General wellbeing; (d) Extraintestinal complications; (e) Antidiarrhoeal drugs; (f) Abdominal mass; (g) Hematocrit; and (h) Body weight. Scores of some items in CDAI are calculated based on patient diary. Total range of score is more than 0. Higher score means more severe disease and especially severe disease was defined as a value of greater than 450.